Rare Disease Patients Face Urgent Need for Systemic Reform

Approximately 36 million Europeans are living with a rare disease, presenting not only a significant medical challenge but also a pressing human rights issue. Diagnostic delays can lead to years of deteriorating health and unnecessary suffering for patients and their families. While advancements in genomics, artificial intelligence, and targeted therapies offer hope for improved care, access to these innovations remains inconsistent across Europe. Even in the Nordic countries, known for their robust health systems, patients with rare diseases struggle to receive equitable and timely treatment.

The economic burden of rare diseases is staggering. Patients report a health-related quality of life that is 32 percent lower than those without a rare condition. The annual cost per patient in Europe, which includes expenses associated with caregiving, averages around €121,900. In Sweden, this figure is slightly lower at €118,000, yet it remains six times higher than costs for individuals without rare diseases. Direct medical costs account for 65 percent of this burden, while caregivers often lose significantly more work hours compared to peers who support patients without rare conditions.

Despite the challenges, there are glimmers of progress. Patients now have a better chance of receiving timely diagnoses and, in some cases, life-altering therapies. The Nordic region leads the way in integrated research and clinical models, creating centers of excellence for rare diseases. Yet, the system is at risk of leaving many behind if reforms are not implemented swiftly.

Current Access Challenges

Access to approved treatments remains a critical issue. Fewer than 10 percent of patients with rare diseases in Europe have access to an approved medication. The Patients W.A.I.T. Indicator indicates significant disparities in access to orphan medicines, with only 28 of the 66 orphan medicines approved between 2020 and 2023 available on average across Europe. Notably, Denmark leads the Nordics with access to 34 of these medicines.

Fragmented decision-making processes exacerbate delays in patient access. On average, patients face a waiting period of 531 days from the time a drug receives marketing authorization to when it becomes available. In countries like Norway and Poland, reimbursement decisions can take over two years, further prolonging the wait for necessary treatments.

Funding for orphan medicines also remains a critical barrier. Despite the availability of more therapies, orphan medicines constitute only 6.6 percent of pharmaceutical budgets and 1.2 percent of health budgets in Europe. Nordic countries such as Sweden, Norway, and Finland allocate even less compared to nations like France and Belgium, highlighting a need for strategic policy shifts rather than financial constraints.

The Path Forward

Policymakers, medical professionals, and patient advocates in the Nordics agree on the urgency of reform. The scientific advancements in rare disease treatment are outpacing the infrastructure designed to deliver these innovations. To ensure that patients benefit from the latest advancements, several measures are necessary.

One key recommendation involves establishing long-term governance and structural funding for rare disease initiatives. Currently, policies are often fragmented and temporary, with national strategies expiring before they can be effectively implemented. Experts emphasize the need for permanent frameworks supported by dedicated funding and clear leadership within health ministries.

Patient organizations play a vital role in advocacy, diagnosis, and access to treatments. Nevertheless, many operate under short-term or volunteer-based funding models. Advocates argue that these organizations require stable support and inclusion in formal policy discussions to ensure that patient perspectives inform decision-making processes.

Investment in research and diagnostics is equally crucial. Sweden is recognized for its advancements in genomic medicine, but funding for advanced testing, particularly for adults, remains limited. Experts advocate for a national health data platform that integrates electronic records, omics data, and patient-reported outcomes. This would facilitate secure sharing and enhance research capabilities.

As breakthroughs in rare disease treatment continue to emerge, the challenge remains: will Europe be prepared to deliver these innovations equitably and swiftly? The Nordic region, equipped with the necessary talent and infrastructure, has the potential to set a benchmark for rare disease care across Europe. Urgent action is essential to ensure that no patient is left waiting while transformative therapies remain inaccessible.

The need for reform is clear. Establishing long-term governance, providing stable support for patient organizations, and investing in research and equitable access can alleviate the burden faced by patients and families. Early intervention not only promotes fairness but also reduces long-term costs for healthcare systems. As the momentum of scientific advancement continues, it is imperative to reform systems to ensure timely and equitable access for all rare disease patients in Europe.